New england journal of medicine8/28/2023 ![]() By 2022, the campaign had gained endorsement from twenty-seven Korean medical societies. In 2015, he spearheaded the implementation of the Choosing Wisely Korea campaign, aimed at reducing unnecessary medical tests and treatments in the country. One of the highlights of Professor Ahn's academic career was hosting the 24th Cochrane Colloquium in the fall of 2016 in Seoul, where colleagues and researchers from around the world gathered for a successful conference that the Cochrane Korea team fondly remembers. In 2014, he authored an influential article published in the New England Journal of Medicine titled "Korea's Thyroid Cancer 'Epidemic' – Screening and Overdiagnosis." This article highlighted Professor Ahn's determination to address overdiagnosis, particularly within the Korean healthcare system. Two years later, Cochrane Korea was officially inaugurated at Korea University as a geographical group of Cochrane.īeyond his Cochrane-related activities, Professor Ahn organized the 8th Guidelines International Network Conference in the summer of 2011, themed "Linking Evidence, Policy, and Practice," marking the first time the conference was held in Asia. In 2007, Professor Ahn led the establishment of the Korean Branch of the Australasian Cochrane Center. This initial gathering in Norway fueled his determination to introduce Cochrane principles in Korea. Professor Ahn's enduring relationship with Cochrane, spanning over twenty years, began when he attended his first Cochrane Colloquium in 2002. Patients concerned about the impact of this drug shortage should contact their healthcare provider.It is with great sadness that we mark the passing of Hyeong Sik Ahn, Director of Cochrane Korea, Professor at the Department of Preventive Medicine, and former Dean of the Graduate School of Public Health at Korea University. Exploring incentives to encourage drug manufacturers to stay in, re-enter or initially enter the market.There often is no transparency on the cause of a drug shortage and many shortages occur with generic drugs. Improving communication with healthcare providers, including extent and timeliness of information.Removing regulatory obstacles faced by manufacturers and the FDA as a way of averting or mitigating drug shortages and allowing drug imports.Establishing an early warning system to help avoid or minimize drug shortages.Relaxing prior authorization requirements from health insurers for alternative therapies so they can be widely used, as appropriate.The MHA supports the following strategies that will address the issue: A survey of medical oncologists published in the New England Journal of Medicine found 83% were unable to prescribe their preferred chemotherapy agent due to shortages. This current shortage follows a national trend of drug shortages impacting healthcare providers for years. “Drug shortages severely hamper a hospital’s ability to provide patients with the best treatment, while forcing hospitals to implement strategies that may increase the cost of care and sometimes do not offer the same effectiveness in treatment.” “The priority of hospitals is delivering the right care to every patient, every time,” said MHA CEO Brian Peters. To reduce the impact of shortages on patients, hospitals are trying many different solutions, including managing existing supply, seeking alternative sources for drugs in short supply, adjusting chemotherapy regimens for impacted patients and working with healthcare systems, as well as state and federal officials, to mitigate these challenges. Both shortage durations are expected to last at least into June 2023. 10, 2023, while carboplatin was reported April 28, 2023. The shortage of cisplatin was originally reported to the U.S. The shortage of these chemotherapy drugs is widespread across the country, impacting hospitals throughout all regions of Michigan.īoth drugs are provided by healthcare providers as injections to oncology patients. The two drugs are cisplatin and carboplatin and are used to treat several types of cancer, including bladder, lung, ovarian and testicular cancers. Manufacturing delays at several pharmaceutical companies are causing nationwide shortages of two critical chemotherapy medications – forcing Michigan hospitals and health systems to find alternative treatments for patients, some of which may be less effective. Keystone Center Patient Safety Organization Michigan Healthcare Human Resources Conference.Ludwig Community Benefit Nomination Form. ![]() Michigan Green Healthcare Awards Nomination Form.Advancing Safe Care Award Nomination Form.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |